Maasoumy B, et al. - In patients with hepatitis C virus (HCV) genotype 1 infection treated with ledipasvir (LDV) and sofosbuvir (SOF) ± ribavirin (RBV) in a large real-world cohort, researchers examined the frequency and prognostic value of detectable and quantifiable HCV RNA results at the end of antiviral treatment (EOT). It was noted that the frequency of detectable HCV RNA at the EOT was 7% in this real-world study with 471 subjects. Data revealed that detectable and even quantifiable HCV RNA results were quite frequent if highly sensitive HCV RNA assays were used. As SVR rates remain high in these patients, treatment prolongation was not indicated.